by Sophine B. Krintel, Laurent Essioux, Assaf Wool, Julia S. Johansen, Ehud Schreiber, Tomer Zekharya, Pinchas Akiva, Mikkel Østergaard, Merete L. Hetland
TNFa inhibitor therapy has greatly improved the treatment of patients with rheumatoid arthritis, however at least 30% do not respond. We aimed to investigate insertions and deletions (INDELS) associated with response to TNFa inhibitors in patients with rheumatoid arthritis (RA). Methodology and Principal Findings
In the DANBIO Registry we identified 237 TNFa inhibitor naïve patients with RA (81% women; median age 56 years; disease duration 6 years) who initiated treatment with infliximab (n?=?160), adalimumab (n?=?56) or etanercept (n?=?21) between 1999 and 2008 according to national treatment guidelines. Clinical response was assessed at week 26 using EULAR response criteria. Based on literature, we selected 213 INDELS potentially related to RA and treatment response using the GeneVa® (Compugen) in silico database of 350,000 genetic variations in the human genome. Genomic segments were amplified by polymerase chain reaction (PCR), and genotyped by Sanger sequencing or fragment analysis. We tested the association between genotypes and EULAR good response versus no response, and EULAR good response versus moderate/no response using Fisher’s exact test. At baseline the median DAS28 was 5.1. At week 26, 68 (29%) patients were EULAR good responders, while 81 (34%) and 88 (37%) patients were moderate and non-responders, respectively. A 19 base pair insertion within the CD6 gene was associated with EULAR good response vs. no response (OR?=?4.43, 95% CI: 1.99–10.09, p?=?7.211×10-5) and with EULAR good response vs. moderate/no response (OR?=?4.54, 95% CI: 2.29–8.99, p?=?3.336×10-6). A microsatellite within the syntaxin binding protein 6 (STXBP6) was associated with EULAR good response vs. no response (OR?=?4.01, 95% CI: 1.92–8.49, p?=?5.067×10-5). Conclusion
Genetic variations within CD6 and STXBP6 may influence response to TNFa inhibitors in patients with RA.